Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer – The VIABLE Phase 3 Randomized Clinical Trial

Vogelzang, N. J., Beer, T. M., Gerritsen, W., Oudard, S., Wiechno, P., Kukielka-Budny, B., Samal, V., Hajek, J., Feyerabend, S., Khoo, V., Stenzl, A., Csöszi, T., Filipovic, Z., Goncalves, F., Prokhorov, A., Cheung, E., Hussain, A., Sousa, N., Bahl, A., Hussain, S., Fricke, H., Kadlecova, P., Scheiner, T., Korolkiewicz, R. P., Bartunkova, J., Spisek, R., Stadler, W., Berg, A. S., Kurth, K., Higano, C. S., Aapro, M., Krainer, M., Hruby, S., Meran, J., Polyakov, S., Machiels, J., Roumeguere, T., Ackaert, K., Lumen, N., Gil, T., Minchev, V., Tomova, A., Dimitrov, B., Koleva, M., Juretic, A., Fröbe, A., Vojnovic, Z., Drabek, M., Jarolim, L., Buchler, T., Kindlova, E., Schraml, J., Zemanova, M., Prausova, J., Melichar, B., Chodacka, M., Jansa, J., Daugaard, G., Delonchamps, N., Duclos, B., Culine, S., Deplanque, G., Le Moulec, S., Hammerer, P., Rodemer, G., Ritter, M., Merseburger, A., Grimm, M., Damjanoski, I., Wirth, M., Burmester, M., Miller, K., Herden, J., Keck, B., Wuelfing, C., Winter, A., Boegemann, M., von Schmeling, I. K., Fornara, P., Jaeger, E., Bodoky, G., Pápai, Z., Böszörményi-Nagy, G., Vanella, P., SotoParra, H., Passalacqua, R., Ferrau, F., Maio, M., Fratino, L., Cortesi, E., Purkalne, G., Asadauskiene, J., Janciauskiene, R., Tulyte, S., Cesas, A., Polee, M., Haberkorn, B., van de Eertwegh, F., van den Berg, P., Beeker, A., Nieboer, P., Zdrojowy, R., Staroslawska, E., Fijuth, J., Sikora-Kupis, B., Karaszewska, B., Fernandes, I., Sousa, G., Rodrigues, T., Dzamic, Z., Babovic, N., Cvetkovic, B., Sokol, R., Mikuláš, J., Gajdos, M., Brezovsky, M., Mincik, I., Breza, J., Arranz, J. A., Calvo, V., Rubio, G., Chapado, M. S., Boreu, P. G., Montesa, A., Olmos, D., Mellado, B., Castellano, D., Puente, J., Karlsson, E. T., Ahlgren, J., Pandha, H., Mazhar, D., Vilarino-Varela, M., Elliott, T., Pedley, I., Zarkar, A., Law, A., Slater, D., Karlin, G., Bilusic, M., Redfern, C., Gaur, R., McCroskey, R., Clarkson, D., Agrawal, M., Shtivelband, M., Nordquist, L., Karim, N., Hauke, R., Flaig, T., Jhangiani, H., Singal, R., Choi, B., Reyes, E., Corman, J., Hwang, C., Appleman, L., McClay, E., Fleming, M., Gunuganti, V., Cheung, E., Gartrell, B., Sartor, A., Williamson, S., Gandhi, J., Schnadig, I., Burke, J., Bloom, S., Shore, N., Mayer, T., Oh, W., Bryce, A., Belkoff, L., Vaishampayan, U., Agarwala, S., Kucuk, O., Agrawal, A., Walsh, W., Poiesz, B., Harshman, L., Dawson, N. and Sharma, S. Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer – The VIABLE Phase 3 Randomized Clinical Trial. JAMA Oncology. 2022. doi: 10.1001/jamaoncol.2021.7298

Date

BioLife Solutions logo

This website uses cookies to ensure you get the best experience on our website.